Roles of insulin-like growth factor II in regulating female reproductive physiology.
by Kayla
No Comments
The number of growth factors involved in female fertility have been studied extensively, but a reluctance to add an important growth factor in the culture medium has been progress in optimizing the growth and implantation of the embryo proceeds, a situation which has ultimately led to reduced pregnancy outcomes is limited. Insulin-like growth factor II (IGF-II) is the most complicated of all the relevant regulated reproductive marked growth factor known to date, and may be the dominant growth factor in human ovarian follicle.
This review aims to briefly summarize what is known about the role of IGF-II in follicle development, maturation of oocytes, embryo development, the successful implantation, placentation, fetal growth, and reduce apoptosis of cells of the placenta, and this strategy is that the growth factor use in the culture system to improve potential development of oocytes and embryos in different species.
Synthesize knowledge about the physiological role of IGF-II in follicle development, oocyte maturation and early development of the embryo must, on the one hand, to deepen our understanding of the overall beneficial effects of potential growth factor in women’s reproductive and on the other hand supports the development (optimization) of results better for assisted reproductive technology.
Roles of insulin-like growth factor II in regulating female reproductive physiology.
Reversibility Acute Kidney Injury in ICU Medical Patients: Predictability urinary performance Tissue Inhibitor of Metalloproteinase-
two x Insulin -As Growth Factor -binding Protein 7 and renal Resistive Index. and urinary biomarkers of renal Doppler sonography are considered as a promising tool to distinguish transient from persistent acute kidney injury. Performance urinary biomarkers, tissue inhibitor of metalloproteinase-2 x insulin-like growth factor-binding protein 7 and renal resistive index to predict acute kidney injury persistent showed conflicting results.
Our aim was to evaluate the performance of tissue inhibitor of metalloproteinase-2 x insulin-like growth factor-binding protein 7 and renal resistive index in predicting the reversibility of acute kidney injury in critically ill patients.Prospective observational study.Twenty-bed medical ICU in a university hospital patients injury.None.Renal .Consecutive with acute renal resistive index measured within 12 hours after admission, and bladder tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 was measured at H0, H6, H12, and H24.
Reversibility of kidney dysfunction was evaluated on day 3. Receiver operating characteristic curves were plotted to evaluate the diagnostic performance of renal resistive index and tissue inhibitor of metalloproteinase-2 x insulin-like growth factor-binding protein 7 to predict acute kidney injury persistent. Overall, 100 patients were included in the 50 with persistent acute kidney injury.
Renal resistive index was higher in the group of persistent renal acute injury. urinary tissue inhibitor of metalloproteinase-2 x insulin-like growth factor-binding protein 7 did not differ significantly at any time between the two groups. Performance tissue inhibitor of metalloproteinase-2 x insulin-like growth factor-binding protein 7 was poor with each area under the receiver operating characteristic curve of 0.57 (95% CI, 0.45 to 0.68), 0.58 ( 95% CI, -0.69 to 0.47), 0.61 (95% CI, 0.50 to .72), and 0.57 (95% CI, 0.46 to 0.68) in H0, H6, H12, and H24.
Description: A polyclonal antibody against IGF1. Recognizes IGF1 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: IHC, ELISA;IHC:1/100-1/300.ELISA:1/10000
Description: A polyclonal antibody against IGF1. Recognizes IGF1 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;WB:1:500-1:2000, IHC:1:50-1:200
Description: A polyclonal antibody against IGF1. Recognizes IGF1 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;WB:1:500-1:2000, IHC:1:50-1:200
Description: A polyclonal antibody against IGF1. Recognizes IGF1 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:25-1:100
Description: A polyclonal antibody against IGF1. Recognizes IGF1 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC; Recommended dilution: IHC:1:200-1:500
Description: Western blot, 0.1-0.5μg/ml, Human, Mouse, Rat;_x000D_Immunohistochemistry (Paraffin-embedded Section), 0.5-1μg/ml, Human, Rat, Mouse, By Heat;_x000D_Immunocytochemistry/Immunofluorescence, 5 μg/ml, Human
Area under the receiver operating characteristic curve for renal resistive index was 0.93 (95% CI, 0.89 to 0.98). An index greater than or equal resistive kidney with acute kidney injury 0.685 persistent predict with 78% (95% CI, 64-88%) sensitivity and 90% (95% CI, 78-97%) specificity.
